This chapter explores the complexities of clinical trials involving MDMA as a treatment for PTSD, emphasizing the monitoring of suicidal tendencies among participants. Concerns regarding self-reporting pressures and the long-term effects of the therapy are discussed, alongside personal accounts of participants' experiences. The chapter underscores the need for comprehensive oversight and understanding as the debate continues on the drug's potential approval for therapeutic use.

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode